Cascadia Announces Closing of C$3M Private Placement
The Placement consisted of the sale of 13,043,479 common shares (each a " FT Share") at a price of $0.23 per FT Share for total gross proceeds of $3,000,000. Each FT Share will qualify as a "flow-through share" within the meaning of subsection 66(15) of the Income Tax Act (Canada) (" Tax Act"). The FT Shares are subject to a hold period under applicable Canadian securities laws until December 16, 2025.
"With this financing and the Granite Creek acquisition completed we are fully funded to complete our first phase of resource expansion work at the Carmacks project," stated Graham Downs, Cascadia's President and CEO."Work is scheduled to commence in early September, with two drills booked and up to 4,000 m of drilling planned this fall. Our technical team continues to review the Carmacks project data, and has identified numerous compelling step-out targets around the existing resource. We're excited to have work underway shortly at this road-accessible property with existing infrastructure and a low cost of drilling."
The gross proceeds from the issuance and sale of the FT Shares will be used for "Canadian exploration expenses" that qualify as "flow-through critical mineral mining expenditures", as both terms are defined in the Tax Act (the " Qualifying Expenditures"). The Qualifying Expenditures will be incurred on or before December 31, 2026, and will be renounced to the subscribers with an effective date no later than December 31, 2025, in an aggregate amount not less than the gross proceeds raised from the issuance of the FT Shares. No finder's fees were paid on any portion of the Placement.
The proceeds from the Placement will be used for critical minerals exploration on Cascadia's Yukon properties, primarily at the Carmacks Project.
About Cascadia
Cascadia's flagship asset is the Carmacks Project in the high-grade Minto copper district in Yukon Territory, Canada. The project is located 35km south of the past-producing Minto mine, which was recently acquired by Selkirk Copper Mines. The Carmacks Project hosts a Measured and Indicated Resource containing 651 Mlbs of copper and 302 koz of gold (36.3 million tonnes grading 0.81 % copper, 0.26 g/t gold, and 3.23 g/t silver and 0.01% molybdenum) with a 2023 PEA demonstrating positive economic potential ($230.5M Post-Tax NPV (5%) and 29% Post-Tax IRR).
Cascadia also has a pipeline of discovery stage copper-gold properties throughout the Yukon Stikine Terrane including its Catch Property, which hosts a copper-gold porphyry discovery where inaugural drill results returned broad intervals of mineralization (116.60 m of 0.31% copper with 0.30 g/t gold). Catch exhibits extensive high-grade copper and gold mineralization across a 5 km long trend, with rock samples returning peak values of 3.88% copper, 1,065 g/t gold, and 267 g/t silver.
QA/QC
The technical information in this news release has been approved by Andrew Carne, P.Eng., VP Corporate Development for Cascadia and a qualified person for the purposes of National Instrument 43-101.
Prospecting grab samples referenced in this release represent highlight results only, and include results from 2024 and previous seasons. Below detection values for copper, gold and silver have been encountered in grab samples in these target areas. For more details on Catch drilling and prospecting results, please see Cascadia's News Releases dated July 25, 2024, and July 19, 2023. The Mineral Resources and economic analysis disclosed here are referenced from the 2023 Technical Report on the Carmacks Project Preliminary Economic Assessment, authored by SGS Canada Inc. for Granite Creek Copper. Pricing for the Carmacks Project PEA base case economic analysis was US $3.75/lb copper, US $1,800/oz gold, and US $22/oz silver at an exchange rate of $1:US$0.75. The results of the Carmacks preliminary economic assessment are preliminary in nature, it includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves, and there is no certainty that the preliminary economic assessment will be realized.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.
Cautionary note regarding forward-looking statements:
This press release may contain "forward-looking information" within the meaning of applicable securities laws. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this press release. Cascadia and Granite Creek undertake no obligation to update forward-looking information, except as required by securities laws.
SOURCE Cascadia Minerals Ltd.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
15 minutes ago
- Cision Canada
HLS Therapeutics Announces New Credit Agreement
TORONTO, Aug. 20, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that the company has entered into a new Credit Agreement (the "Agreement") with National Bank of Canada ("National Bank") as administrative agent which provides for committed credit facilities denominated in Canadian dollars of up to CAD $107 million (USD ~$77.5 million). National Bank serves as administrative agent and lead arranger, with the Toronto-Dominion Bank, Royal Bank of Canada, and Innovation Federal Credit Union as syndicate members. The Agreement replaced HLS's credit facility with JP Morgan Chase Bank, N.A. which had a maturity date of August 11, 2026. On closing, the proceeds from the new term facility were used to repay the Company's existing credit agreement in full. The new Agreement has a maturity date of August 19, 2029. The Agreement consists of a CAD $79 million term credit facility, a CAD $14 million delayed draw facility and a CAD $14 million revolving credit facility. In addition, HLS can increase facilities further through an uncommitted CAD $40 million accordion facility (subject to Lender agreement). Interest on the Agreement accrues at a rate per month equal to the sum of the Canadian Overnight Repo Rate Average ("CORRA") plus a range of 2.25% to 3.50% depending on the leverage ratio of the Company at the time. Interest rate spreads are 25-50 basis points below the rate in the Company's prior credit agreement, providing improved cash flow through reduced interest expense. The debt is denominated in Canadian dollars, creating a natural currency hedge against the Company's predominantly Canadian operations. In addition to the interest rate spread savings detailed above, HLS will achieve further interest rate savings in excess of 100 basis points based on current market interest rates, as a result of the differential between US dollar and Canadian dollar base rates. "We are pleased to finalize this new credit agreement with National Bank and our syndicate partners, which reflects their confidence in our outlook," said John Hanna, CFO of HLS Therapeutics. "The Agreement delivers improved terms that reflect our strengthened financial position and provides enhanced financial flexibility and cash flow to pursue our capital allocation priorities such as share buybacks and portfolio expansion." ABOUT HLS THERAPEUTICS INC. Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: FORWARD LOOKING INFORMATION This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities and expectations regarding financial performance. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 12, 2025, and Management's Discussion and Analysis dated August 13, 2025, both of which have been filed on SEDAR+ and can be accessed at Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. SOURCE HLS Therapeutics Inc.
Calgary Herald
28 minutes ago
- Calgary Herald
Posthase: Renters are spending a scary amount on housing
Article content Canadian renters are spending an ever-growing amount of their paycheques on rent, even though they may qualify for a mortgage. Article content Article content Nationally, they are spending 37.6 per cent of their income on rent, according to analysis from SingleKey Inc., falling just below the 40 per cent 'crisis' level. Article content But Toronto renters have already reached the crisis level by spending 41.1 per cent of their salaries on housing, or an average of $2,899 per month. Article content Article content The average rent in Canada is $2,200 per month, with Vancouver's $3,095 per month rate being the most expensive city for renters. Article content Article content It's no wonder renters have a hard time paying the bills. A recent Equifax Canada report said non-mortgage holders were twice as likely to miss a credit payment compared to those with a mortgage. Article content 'While the overall delinquency rate appears to be levelling off, the underlying story is far more complex,' Rebecca Oakes, vice-president of advanced analytics at Equifax Canada, said in a release. 'We continue to see a growing divide between mortgage and non-mortgage consumers, and continued financial strain among younger Canadians, who are facing a slower job market and rising costs.' Article content Overall, 1.4 million Canadians missed a credit payment in the second quarter of 2025, while consumer debt climbed to $2.58 trillion, Equifax said. Article content Article content This comes despite rents for condos and apartments falling 3.6 per cent year over year in July, marking the 10th consecutive month where Canada's rents have fallen year over year, according to data. Article content Article content The good news for renters is that it doesn't look like rent will be going up anytime soon. Article content 'The 3.6 per cent year-over-year rent decline in July is greater than the 2.7 per cent decline recorded in June and suggests that rent declines are likely to continue compounding,' said in its report. Article content Despite the challenges of paying their bills, many renters might still qualify for a mortgage. The average credit score among renters is 694, SingleKey said, which is above the 680 threshold needed for approval at many major banks.
Toronto Star
an hour ago
- Toronto Star
American Tungsten Advances Zero Level Rehabilitation at IMA Mine
Vancouver, BC, Aug. 20, 2025 (GLOBE NEWSWIRE) — American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) ('American Tungsten' or the 'Company') American Tungsten is pleased to report significant progress in the ongoing rehabilitation of the Zero Level portal at its IMA Mine site, as part of its commitment to safety, operational excellence, and regulatory compliance. Weekly Progress Highlights (Week Ending August 16, 2025):
